1Thomas F, LiJscher, Matthias B, et al .Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs[J].Circulation, 2000,102: 2434.
2Channick RN, Sitbon O, Barst RJ, et al .Endothelin receptor antagonists in pulmonary arterial hypertension [J] .J Am Coll Cardiol,2004, 43(12 Suppl) :62.
4Suleman N, Frost AE .Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension [J].Chest, 2004,126(3) : 808.
5Jane G,Neil R,Malcolm F,et al .Endothelin A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure.A comparison of selective and combined endothelin receptor blockade [J].Circulation , 2004,109:1186.
6Paul M, Houssaine B, Vincent R, et al. Selective endothelin-A versus combined endothelin- A/endothelin-13 receptor blockade in rat chronic heart failure[J].Circulation , 2000,102: 491.
7Anand I, McMurray J,Cohn JN, et al .Long - term effects of darusentan on left - ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure(EARTH) : randomised, double- blind, placebo- controlled trial[J] . Lancet, 2004,364(9431) :347.
8Dingemanse J, Clozel M,Van Giersbergen PL.Entry 2 into 2 humans study with tezosentan, an intravenous dual endothelin receptor an 2 tagonist[J].J Cardiovasc Pharmacol, 2002,39(6) : 7952802.
9Cotter G, Kiowski W, Kaluski E, et al .Tezosentan (an intravenous endothelin receptor A/ B antagonist) reduces peripheral resistanceand increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure[J].Eur J Heart Fail ,2001,3(4):4 572 461.
10Leonarda G, Anthony N, Ughetta B, et al . Ischemiareperfusion injury at the microvascular level: treatment by endothelin A- selective antagonist and evaluation by myocardial contrast echocardiography[J].Circulation, 2000,102 : 3111.
